By Fineline Cube 
Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a RMB 100 million (USD 13.7 million) Series B+ funding round. The investment was co-led by Lapam Capital and Dalton Ventures, with participation from existing investor Lilly Asia Ventures and other institutional investors. The funds will be used to accelerate pivotal clinical trials and regulatory submissions for the company’s heart failure management systems.
Company and Product Pipeline
Founded in 2020, United InnoMed specializes in closed-loop neuromodulation systems for heart failure patients. Its pipeline includes:
- Chronic Heart Failure System: A long-term implantable device combining cardiac resynchronization therapy (CRT) with hemodynamic monitoring.
- Acute Decompensated HF System: A transient electrical stimulation device designed for hospitalized patients requiring circulatory support.
Clinical Progress and Future Outlook
Both systems have completed GLP-compliant animal studies and are preparing for NMPA-registered clinical trials in China. This funding milestone positions United InnoMed to advance its innovative solutions for heart failure management.-Fineline Info & Tech